N-hydroxypiperidine-4-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-hydroxypiperidine-4-carboxamide
• 化学式: C₆H₁₂N₂O₂
• 分子量: 144.17
• InChiKey: DKGZULAWTBQCOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-n-butoxy-benzenesulfonyl)-1-(3-phenoxy-propyl)-piperidine-4-carboxylic acid 、 N-hydroxypiperidine-4-carboxamide 生成 4-(4-n-butoxy-benzenesulfonyl)-1-(3-phenoxy-propyl)-piperidine-4-carboxylic acid hydroxyamide
  参考文献：
  名称：

  N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors

  摘要：

  基质金属蛋白酶（MMPs）是一组酶，已被认为与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个亚组，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-&agr;转换酶（TACE）是一种促炎细胞因子，催化膜结合型TNF-&agr;前体蛋白形成TNF-&agr;。因此，预计MMPs和TACE的小分子抑制剂具有治疗各种疾病的潜力。本发明提供低分子量、非肽类基质金属蛋白酶（MMPs）和TNF-&agr;转换酶（TACE）的抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4如本文所定义。

  公开号：

  US06331563B1

文献信息

• LTA4H modulators and uses thereof
  申请人：Barchuk William T.

  公开号：US20080194630A1

  公开（公告）日：2008-08-14

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  白三烯A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的方法。
• [EN] BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS<br/>[FR] DERIVES DE BENZIMIDAZOLE, DE BENZTHIAZOLE ET DE BENZOXAZOLE ET UTILISATION DE CEUX-CI COMME MODULATEURS LTA4H
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005012296A1

  公开（公告）日：2005-02-10

  Leukotriene A4 hydrolase (LTA4H) inhibitors of formula I, compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation, wherein X is selected from the group consisting of NR5, O, and S, with R5 being one of the H and CH3; Y is selected from the group consisting of CH2 and O; R4 is selected from the group consisting of H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3.

  白三烯A4水解酶（LTA4H）的抑制剂I式，含有它们的组合物，以及它们用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的用途，其中X从NR5、O和S组成的组中选择，其中R5是H和CH3中的一个；Y从CH2和O组成的组中选择；R4从H、O 、Cl、F、Br、I、OH、NH2、CN、CF3组成的组中选择。
• [EN] GLYCINE METABOLISM MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU MÉTABOLISME DE LA GLYCINE ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2018021977A1

  公开（公告）日：2018-02-01

  The present invention relates to a compound of general formula (I) and/or its solvates, hydrates and pharmaceutically acceptable salts, which are modulators of glycine metabolism. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with glycine metabolism or a pathway where glycine decarboxylase (GLDC, or glycine cleavage system) plays a role. In a preferred embodiment the disorders/conditions/disease is cancer, inflammatory conditions, Alzheimer's disease, metabolic disorders and CNS disorders.

  本发明涉及一般式(I)的化合物及/或其溶剂合物、水合物和药学上可接受的盐，这些化合物是甘氨酸代谢调节剂。本发明还涉及其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗涉及或与甘氨酸代谢或甘氨酸脱羧酶（GLDC，或甘氨酸裂解系统）发挥作用的病症/疾病/疾病的用途。在一个首选实施例中，疾病/疾病是癌症、炎症性疾病、阿尔茨海默病、代谢性疾病和中枢神经系统疾病。
• [EN] BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS<br/>[FR] DERIVES DE BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LTA4H
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005012297A1

  公开（公告）日：2005-02-10

  Leukotriene A4 hydrolase (LTA4H) inhibitors of Formula (I), compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation. Wherein X is selected from the group consisting of NR5, O, and S, with R5 being on of H and CH3; Y is selected from the group consisting; W is selected from the group consisting Of CH2 and CHR1-CH2, with R1 being one H and OH, wherein R1-attached carbon member in said CHR1-CH2 is not directly attached; R4 is selected from the group consisting of H, OCH3, CI, F Br, OH, NH2, CN, CF3 and CH3; R6 is H or F; and R2 and R3 are each independently selected from various groups.

  Leukotriene A4水解酶（LTA4H）的Formula（I）抑制剂，含有它们的组合物以及它们用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的用途。其中X选择自NR5，O和S组，其中R5是H和CH3之一; Y选择自组中，W选择自CH2和CHR1- 组，其中R1是H和OH之一，其中所述CHR1- 中的R1-连接碳成员不直接连接; R4选择自H，O ，CI，F Br，OH，NH2，CN，CF3和 组; R6是H或F; R2和R3各自独立地选择自各种组。
• LTA4H Modulators
  申请人：Axe U. Frank

  公开号：US20050043379A1

  公开（公告）日：2005-02-24

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  Leukotriene A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关的病症的使用方法。